Search Results - "Miller, Talia"

Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US by Mukherjee, Sudipto, Savill, Kristin M., Gajra, Ajeet, Gentile, Danielle, Falkenstein, Angelica, Miller, Talia, Laney, JaLyna, McBride, Ali

Get full text

Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib by Kish, Jonathan K., Kee, Arianna, Abraham, Pranav, Copher, Ronda, Miller, Talia, Gerds, Aaron T.

“…Introduction: Relief of symptoms and splenomegaly are important treatment goals for all patients with myelofibrosis (MF). Until 2019, ruxolitinib (RUX) was the…”
Get full text

Real-world disease burden for patients (pts) with myelofibrosis (MF) treated with ruxolitinib (RUX) by Gerds, Aaron Thomas, Kish, Jonathan, Parikh, Kejal, Liassou, Djibril, Miller, Talia, Copher, Ronda

“…Abstract only e19539 Background: MF is an aggressive myeloid neoplasm and until recently RUX was the only treatment available. Real-world, long-term outcomes…”
Get full text

Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns by Mukherjee, Sudipto, Brown-Bickerstaff, Cherrishe, McBride, Ali, Gajra, Ajeet, Gentile, Danielle, Falkenstein, Angelica, Miller, Talia, Laney, JaLyna, Savill, Kristin M., Makinde, Adeola Y.

Get full text

Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among U.S. patients with lower-risk myelodysplastic syndromes (LR-MDS) by Mukherjee, Sudipto, Savill, Kristin M. Zimmerman, Gajra, Ajeet, Kish, Jonathan K., Brown-Bickerstaff, Cherrishe, Gentile, Danielle, Falkenstein, Angelica, Miller, Talia, Laney, Jalyna R., McBride, Ali

“…e19065 Background: ESAs are used in first-line treatment for symptomatic or transfusion-dependent anemia in patients (pts) with LR-MDS. Ultimately, the…”
Get full text

Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States by Zimmerman Savill, Kristin M., Gajra, Ajeet, Price, Kwanza, Kish, Jonathan K., Brown-Bickerstaff, Cherrishe, Falkenstein, Angelica, Miller, Talia, Laney, JaLyna, Mukherjee, Sudipto

“…Introduction: Myelodysplastic syndromes (MDS) comprise a group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias,…”
Get full text

Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC) by Tabah, Ashley, Huggar, David, Kish, Jonathan, Bapat, Bela, Liassou, Djibril, Gajra, Ajeet, Miller, Talia, Copher, Ronda, Patel, Manali I.

“…Abstract only e21717 Background: Pem+carbo+pac or nab-pac are approved first-line (1L) treatments for metastatic squamous NSCLC since 10/30/2018. Difference in…”
Get full text

Abstract P5-14-13: Real-world dosing and CBC monitoring in patients with metastatic breast cancer during palbociclib plus letrozole therapy by Kish, Jonathan, Miller, Talia, Nero, Damion, Liassou, Djibril, Liu, Xianchen, McRoy, Lynn, Feinberg, Bruce, Zhan, Lin, Trocio, Jeffrey

“…Abstract Background: Palbociclib in combination with letrozole (P+L) was the first cyclin-dependent-kinase 4/6 inhibitor approved in the U.S for treatment of…”
Get full text

Clinician interview results about the experiences of their patients who report side effects with statin treatment by Vrablik, Michal, Catapano, Alberico, Wiklund, Olav, Grove, Alyson, Miller, Talia, Mccarrier, Kelly, Qian, Yi, Rane, Pratik, Martin, Mona

Get full text

Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy by Mougalian, Sarah S, Feinberg, Bruce A, Wang, Edward, Alexis, Karenza, Chatterjee, Debanjana, Knoth, Russell L, Nero, Damion, Miller, Talia, Liassou, Djibril, Kish, Jonathan K

“…To examine the effectiveness of eribulin mesylate for metastatic breast cancer post cyclin-dependent kinase inhibitor (CDKi) 4/6 therapy. US community…”
Get full text

Quality of life patient-reported outcomes for locally advanced cutaneous melanoma by Weitman, Evan S, Perez, Matthew, Thompson, John F, Andtbacka, Robert H I, Dalton, Jo, Martin, Mona L, Miller, Talia, Gwaltney, Chad, Sarson, David, Wachter, Eric, Zager, Jonathan S

“…Locally advanced cutaneous melanoma has marked quality-of-life implications; however, the patient experience of symptom management and subsequent impact on…”
Get full text